Short stature remains the most common reason for referral to a pediatric Endocrinologist and its management remains a challenge. One of the main controversies is the diagnosis of idiopathic short stature and the role of new technologies for genetic investigation of children with inadequate growth.

Complexities in management of children with short stature includes selection of who should receive interventions such as recombinant human growth hormone, and how should this agent dose be adjusted during treatment. Should anthropometrical data be the primary determinant or should biochemical and genetic data be used to improve growth response and safety? Furthermore, what is considered a suboptimal response to growth hormone therapy and how should this be managed?

Treatment of children with short stature remains a “hot” topic and more data is needed in several areas. These issues are reviewed in this paper.

身材矮小仍然是转诊给儿科内分泌科医生的最常见原因，其管理仍然是一个挑战。主要争议之一是特发性矮小身材的诊断以及新技术对发育不足的儿童进行基因调查的作用。

身材矮小儿童的治疗复杂性包括选择谁应接受干预，例如重组人生长激素，以及在治疗期间应如何调整该药物剂量。人体测量数据是主要决定因素还是应使用生化和遗传数据来改善生长反应和安全性？此外，什么是对生长激素疗法的次佳反应，应如何加以管理？

对身材矮小儿童的治疗仍然是一个“热门”话题，在几个领域还需要更多数据。这些问题在本文中进行了回顾。